PWRM, Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

PWRM, Power 3 Medical Products Inc, PWRM.OB

Dr Stock Pick HOT News & Alerts!

Power3 Medical Products, Inc. Files for 3 Patents on Blood Test

for Diagnosis of Early Stage Breast Cancer

 

Monday August 31, 2009

Power3 Medical Products, Inc. Files for 3 Patents on Blood Test for Diagnosis of Early Stage Breast Cancer

Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced recently that the company made significant advances in the technology for their BC-SeraPro� serum protein based blood test for diagnosis of early stage breast cancer, as disclosed in recent filings of three pending US utility patent applications.

�Roughly 200,000 women in the US and 1.2 million women worldwide are diagnosed with breast cancer each year. In the US roughly 40,000 women die of the disease because the cancer is caught too late. In fact, nearly ��½ of all cancers are missed as false negatives and 75% of the biopsies of suspected breast cancer performed are false positive and therefore could have been avoided if there was a more accurate test that could be made readily available,� said Ira L. Goldknopf, Ph.D., president and chief scientific officer of Power3. �We now have made strides towards this goal through refinements in our blood test for early stage detect! ion of b reast cancer.�

As disclosed in the patent applications, Power3 has identified a group of 22 blood serum proteins with abnormal concentrations in women with breast cancer. Using the company�s BC-SeraPro platform, Power3 used these protein biomarkers to distinguish women with breast cancer from those with benign abnormal breast conditions and with normal breasts with sensitivities and specificities in the 80-90% range, in retrospective banked and prospective newly drawn samples from patients and controls. The biomarkers also distinguish between women with purely invasive primary breast cancer and women who also have ductal carcinoma in situ which is often missed in mammograms. In addition, following the �Principals of Omic Medicine� that Dr. Goldknopf is promoting at international scientific meetings in the US and China, the company has disclosed methods for making biomarker specific antibodies for development of a user friendly commercial test for breast cancer.

“We are enthusiastic about the increased value of BC-SeraPro with these 3 exemplary patent filings. Although we are striving to commercialize with our tests, we also recognize that this work has potential to alleviate much suffering,” commented Ms. Helen R. Park, CEO of Power3. “Thus we will be publishing our results in the near term.”

About Power3 Medical Products, Inc.:

Power3 Medical Products, Inc. (OTCBB:PWRM) (www.Power3Medical.com), is a leading Bio Medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets.

Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. The C! ompany c ontinues to evolve and enhance its IP portfolio.

Forward Looking Statement
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.

Helen R. Park, M.S., hpark@power3medical.com
Power3 Medical Products, Inc.
3400 Research Forest Drive
Suite B2-3
Woodlands, TX 77381
USA
Phone: 281-466-1600

Source: Power3 Medical Products, Inc.

Keep a close eye on PWRM today, do your homework, and like always BE READY for the ACTION!

Related Articles:

Credit, Consumer Worries Slap Stocks

Abercrombie: The “Worst Appears Over,” Says Analyst

Tags: 2014 Penny Stocks ,Best Stocks To Buy 2014 ,Best Stocks To Buy For 2014 ,Best Stocks To Invest In 2014 ,Risk Management ,Top Dividend Stocks 2012